SCHEMBL6539142

SCHEMBL6539142

COCC(C)n1nc(-c2cc(Cl)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.36
ADORA1 P30542 2/20 0.36
POLB P06746 2/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
FGFR1 P11362 4/20 0.35
FGFR2 P21802 3/20 0.35
FGFR3 P22607 3/20 0.35
PDE4B Q07343 2/20 0.34
PDE4A P27815 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
PDE5A O76074 1/20 0.34
PDE3A Q14432 1/20 0.34
MAP3K12 Q12852 1/20 0.34
LMNA P02545 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538514 0.88 POLB (0.39) ADORA2AADORA1POLBFGFR1FGFR2
SCHEMBL6538926 0.87 POLB (0.39) ADORA2AADORA1POLBFGFR1FGFR2
SCHEMBL6133694 0.82 ADORA1 (0.46) ADORA2AADORA1LMNAMAPTKMT2A
SCHEMBL6539249 0.80 TP53 (0.40) POLBPDE4BPDE4APDE4CPDE4D
SCHEMBL6539151 0.79 ABL1 (0.48) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL6538508 0.79 SRC (0.43) POLBFGFR1FGFR2FGFR3SRC
SCHEMBL6538310 0.79 BRD4 (0.42) ADORA2AADORA1FGFR1TP53MAPT
SCHEMBL6538523 0.78 TP53 (0.42) POLBPDE4BPDE4APDE4CPDE4D
SCHEMBL6539117 0.78 PDE1A (0.43) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL6538377 0.77 SRC (0.41) FGFR1FGFR2FGFR3LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 ADORA2A 2/4885ADORA1 1/4885POLB 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.